Le Lézard
Classified in: Health, Science and technology

73% of Respondents Say One or More Diseases Run in Their Family; Just 6% Don't Want Genetic Testing -- Wamberg Genomic Survey



LA JOLLA, Calif., Dec. 7, 2017 /PRNewswire/ -- Seventy-three percent of respondents noted that common diseases run in their family.  The top diseases cited were diabetes 37%, cancer 35%, heart disease 32%, and depression/mental health issues 31%.  Just 6% would decline free genetic testing to better predict future occurrence of diseases. Fifty-three percent (53%) of respondents noted that they would definitely accept free genetic testing to better predict future occurrence of diseases, another 29% may want it, and 12% were unsure.

Wamberg Genomic Advisors' mission is to make genomic testing readily available at prices everyone can afford. The firm's focus is on delivering genomic products and services to employers and their employees via their trusted benefit brokers, and policyholders of life insurance companies (PRNewsfoto/Wamberg Genomic Advisors)

Results are based on Wamberg Genomic Consumer Survey, which queried 536 U.S. consumers from 26 to 64 years old with employer-sponsored health insurance. Survey Sampling International (SSI) fielded the survey in October/November 2017.

According to Dr. Phil Smalley, Chief Medical Director of Wamberg Genomic Advisors, "These results indicate that the public seems to understand that knowing their genetics can help lower their risk of developing diseases that run in their family."

Results from the survey questions are below:

Do any of these diseases run in your family? *

If you were offered free genetic testing to better predict future occurrence of diseases and the results were private and confidential, would you want to get your own genetics tested?

For the first time, individuals and their families can access the following tests and reports to help their care providers better manage health:

Other results of the survey revealed the following:

About the Survey
The Wamberg Genomic Consumer Survey queried 536 U.S. consumers 26-64. The survey was fielded by Survey Sampling International (SSI) in October/November 2017. Data for the survey was collected via an opt-in panel. The margin of error was 4%.

About Survey Sampling International:

Survey Sampling International (SSI) has been the premier global provider of data solutions and technology for consumer and business-to-business survey research for 40 years.  For more information, go to www.surveysampling.com.   

About Wamberg Genomic Advisors:

Wamberg Genomic Advisors' mission is to make genomic testing readily available at prices everyone can afford. Our focus is on delivering genomic products and services to employers and their employees via their trusted benefit brokers, and policyholders of life insurance companies. To learn more, visit wamberggenomic.com.

*Note percentages can add to more than 100% as respondents can choose multiple answers

SOURCE Wamberg Genomic Advisors


These press releases may also interest you

at 00:00
FAIRFIELD, N.J., Aug. 22, 2018 /PRNewswire-PRWeb/ -- In a review of many of the most recent articles about the nation's health care system, two common themes seem to be evolving. First, the current system is getting more expensive, from some cost...

21 aoû 2018
Recently, a review paper on the "Biological Role and Therapeutic Potential of IDH Mutations in Cancer" was published in Cancer Cell, the authoritative international academic journal. The paper was led by Yan Hai, chair professor at Duke University...

21 aoû 2018
PASADENA, Calif., Aug. 21, 2018 /PRNewswire-PRWeb/ -- An August 7 article in The Economic Times discusses research by the WHO (World Health Organization) which found that eating processed starch seemed to increase the risk of tooth decay while,...

21 aoû 2018
Asia's largest exhibition and conference dedicated to the Medical Device Design and Manufacturing industry, "Medtec Japan 2019" will be held in Tokyo from 18th Mon - 20th Wed March 2019. Over 560 exhibitors from some 25...

21 aoû 2018
Today, the Canadian Medical Association (CMA) presented its 2018 awards as part of its annual recognition of outstanding individuals who have made an exceptional contribution to medicine and the health care system. "Taking a moment to highlight and...

21 aoû 2018
Ascensia Diabetes Care today announced the launch of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in Australia. The easy-to-use CONTOUR®NEXT ONE smart meter seamlessly connects to the CONTOUR®DIABETES app via Bluetooth® connectivity,...




News published on 7 december 2017 at 18:02 and distributed by: